FWM
ALNY icon

FSA Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

FSA Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.65K Hold
8
– – ﹤0.01% 441
2025
Q2 		$2.61K Hold
8
– – ﹤0.01% 448
2025
Q1 		$2.16K Hold
8
– – ﹤0.01% 434
2024
Q4 		$1.88K Hold
8
– – ﹤0.01% 492
2024
Q3 		$2.2K Buy
+8
New +$2.08K ﹤0.01% 484
2024
Q1 		$1.2K Hold
8
– – ﹤0.01% 570
2023
Q4 		$2K Buy
+8
New +$1.36K ﹤0.01% 516

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

FSA Wealth Management's ALNY Position: Q3 2025 in Review

FSA Wealth Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2025 at 8 shares worth $3.65K. The position accounts for ﹤0.01% of the portfolio, ranked #441.

FSA Wealth Management first reported a position in ALNY in Q4 2023 and has held it in 7 quarters since. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • FSA Wealth Management held 8 shares of Alnylam Pharmaceuticals worth $3.65K as of Q3 2025.
  • FSA Wealth Management left its Alnylam Pharmaceuticals share count unchanged in Q3 2025.
  • Alnylam Pharmaceuticals made up ﹤0.01% of FSA Wealth Management's portfolio in Q3 2025, its #441 holding.
  • FSA Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
  • 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on FSA Wealth Management's 13F filing for Q3 2025, filed 17 Nov 2025.